<DOC>
	<DOCNO>NCT02566044</DOCNO>
	<brief_summary>This study multiple dos inhale QBW276 patient cystic fibrosis top standard care . The study divide 3 Cohorts . Cohorts 1 2 design randomize , double-blind , placebo-controlled , parallel arm , multiple dose study assess safety , tolerability , pharmacokinetics , preliminary efficacy inhale QBW276 1 week ( cohort 1 ) 2 week ( cohort 2 ) patient cystic fibrosis regardless genotype . In contrast , cohort 3 randomize , double-blind , placebo-controlled , cross-over design , multiple dose study assess efficacy , safety , tolerability pharmacokinetics inhale QBW276 4 week patient cystic fibrosis homozygous F508del mutation . The primary rationale cohort 3 ass efficacy high unmet need cystic fibrosis patient population .</brief_summary>
	<brief_title>Safety , Pharmacokinetics Pharmacodynamics Study Inhaled QBW276 Patients With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Cohorts 1 2 = genotype standard care treatment Cohort 3 = F508del homozygotes standard care time FEV₁between 40 100 % LCI2.5 ≥ 8 FEV₁is 80 % Adrenal electrolyte abnormality Lung transplant Autonomic dysfunction ( e.g . recurrent episode fainting , palpitation , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Cystic Fibrosis</keyword>
</DOC>